Gilles Besin, Ph.D., CSO at Orbital: “Elegen's unique expertise in supplying...IVT-ready synthetic DNA constructs is very attractive to us. By leveraging Elegen’s platform, we see the opportunity to accelerate the development of our novel mRNA therapies."

Following the resounding success of its Early Access Program (EAP) for high-complexity DNA, launched in May 2023, Elegen witnessed overwhelming demand. EAP participants received long and highly complex DNA sequences, previously deemed challenging or requiring months for synthesis by other providers.

Elegen’s expanded sequence acceptance criteria now allow the synthesis of long linear dsDNA encompassing a myriad of complex elements, including inverted terminal repeats (ITRs), difficult promoters and enhancers, hairpins, homopolymers, short tandem repeats (STRs), long repeats, and regions with high GC content. This enhancement provides researchers with unprecedented flexibility and efficiency in exploring diverse sequence spaces.

Orbital Therapeutics, an innovative player in RNA-based medicine advancements, participated in Elegen's EAP and lauded the expedited delivery of complex constructs. Raghav Poudyal, Ph.D., Associate Director of RNA process development at Orbital Therapeutics, remarked, “Receiving these molecules in a matter of weeks has helped us save a considerable amount of time during the development of a new mRNA therapeutic."

Gilles Besin, Ph.D., Chief Scientific Officer at Orbital, further emphasized the value of Elegen’s platform in accelerating therapeutic development, stating, “Elegen's unique expertise in supplying long, accurate, very complex IVT-ready synthetic DNA constructs is very attractive to us."

With the successful completion of Early Access and Beta Programs, Elegen has updated its online ordering portal to accept sequences with very high complexity, reinforcing its commitment to empowering researchers with cutting-edge DNA solutions.

Matt Hill, Ph.D., founder, and CEO of Elegen, highlighted the significance of this enhancement in driving scientific innovation, stating, “Providing our customers with very complex DNA in a matter of days enables them to explore a broader sequence space much faster. This upgrade reflects our commitment to pushing the boundaries of DNA manufacturing innovation."

Since its commercial launch in Q1 2023, ENFINIA DNA has evolved rapidly, with expanded yield options and strategic collaborations, including a partnership with GSK for vaccine and genetic medicine development. This latest enhancement underscores Elegen’s unwavering dedication to pioneering solutions for DNA manufacturing, marking yet another milestone in its mission to revolutionize scientific research and therapeutic development.